+

WO2002031110A3 - Therapie genique aux cellules souches hematopoietiques - Google Patents

Therapie genique aux cellules souches hematopoietiques Download PDF

Info

Publication number
WO2002031110A3
WO2002031110A3 PCT/IB2001/002739 IB0102739W WO0231110A3 WO 2002031110 A3 WO2002031110 A3 WO 2002031110A3 IB 0102739 W IB0102739 W IB 0102739W WO 0231110 A3 WO0231110 A3 WO 0231110A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
thymus
patient
hematopoietic stem
lhrh
Prior art date
Application number
PCT/IB2001/002739
Other languages
English (en)
Other versions
WO2002031110A2 (fr
Inventor
Richard Boyd
Original Assignee
Richard Boyd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR0745A external-priority patent/AUPR074500A0/en
Priority claimed from US09/966,576 external-priority patent/US20020071833A1/en
Priority to JP2002534480A priority Critical patent/JP2004511495A/ja
Priority to BR0114639-4A priority patent/BR0114639A/pt
Priority to AU2002216320A priority patent/AU2002216320C1/en
Priority to APAP/P/2003/002800A priority patent/AP2003002800A0/en
Application filed by Richard Boyd filed Critical Richard Boyd
Priority to CA002462073A priority patent/CA2462073A1/fr
Priority to KR10-2003-7005255A priority patent/KR20030082542A/ko
Priority to IL15541301A priority patent/IL155413A0/xx
Priority to EP01986714A priority patent/EP1357978A4/fr
Priority to AU1632002A priority patent/AU1632002A/xx
Publication of WO2002031110A2 publication Critical patent/WO2002031110A2/fr
Publication of WO2002031110A3 publication Critical patent/WO2002031110A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

L'invention concerne des méthodes de thérapie génique utilisant des cellules souches hématopoïétiques, des cellules progénitrices lymphoïdes et/ou des cellules progénitrices myéloïdes. Les cellules sont génétiquement modifiées afin de produire un gène qui soit exprimé dans ces cellules et leur descendance après différenciation. Dans un mode de réalisation, les cellules contiennent un gène ou un fragment de gène qui confère aux cellules une résistance contre l'infection par le VIH et/ou la réplication de celui-ci. Les cellules sont administrées à un patient conjointement au traitement afin de réactiver le thymus du patient. Les cellules peuvent être autologues, syngéniques, allogéniques ou xénogéniques, étant donné que la tolérance à des cellules étrangères est créée chez le patient au cours de la réactivation du thymus. Dans un mode de réalisation préféré, les cellules souches hématopoïétiques sont CD34+. Le thymus du patient est réactivé par disruption de la signalisation induite par des stéroïdes sexuels vers le thymus. Dans un mode de réalisation préféré, cette disruption est créée par administration d'agonistes de LHRH, d'antagonistes de LHRH, d'anticorps du récepteur anti-LHRH, des vaccins anti-LHRH ou des combinaisons de ces derniers.
PCT/IB2001/002739 2000-10-13 2001-10-12 Therapie genique aux cellules souches hematopoietiques WO2002031110A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU1632002A AU1632002A (en) 2000-10-13 2001-10-12 Hematopoietic stem cell gene therapy
EP01986714A EP1357978A4 (fr) 2000-10-13 2001-10-12 Therapie genique aux cellules souches hematopoietiques
BR0114639-4A BR0114639A (pt) 2000-10-13 2001-10-12 Terapia genética de célula tronco hematopoiética
AU2002216320A AU2002216320C1 (en) 2000-10-13 2001-10-12 Hematopoietic stem cell gene therapy
APAP/P/2003/002800A AP2003002800A0 (en) 2000-10-13 2001-10-12 Hematopoietic stem cell gene therapy
JP2002534480A JP2004511495A (ja) 2000-10-13 2001-10-12 造血幹細胞遺伝子療法
CA002462073A CA2462073A1 (fr) 2000-10-13 2001-10-12 Therapie genique aux cellules souches hematopoietiques
KR10-2003-7005255A KR20030082542A (ko) 2000-10-13 2001-10-12 조혈 간세포 유전자 요법
IL15541301A IL155413A0 (en) 2000-10-13 2001-10-12 Hematopoietic stem cell gene therapy

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US79528600A 2000-10-13 2000-10-13
US79530200A 2000-10-13 2000-10-13
US09/795,286 2000-10-13
AUPR0745 2000-10-13
AUPR0745A AUPR074500A0 (en) 2000-10-13 2000-10-13 Treatment of t cell disorders
US09/795,302 2000-10-13
US75891001A 2001-01-10 2001-01-10
US09/758,910 2001-01-10
US09/966,576 US20020071833A1 (en) 1999-04-15 2001-09-26 Hematopoietic stem cell gene therapy
US09/966,576 2001-09-26
US96951001A 2001-10-01 2001-10-01
US09/969,510 2001-10-01

Publications (2)

Publication Number Publication Date
WO2002031110A2 WO2002031110A2 (fr) 2002-04-18
WO2002031110A3 true WO2002031110A3 (fr) 2002-06-20

Family

ID=27542982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/002739 WO2002031110A2 (fr) 2000-10-13 2001-10-12 Therapie genique aux cellules souches hematopoietiques

Country Status (10)

Country Link
EP (1) EP1357978A4 (fr)
JP (1) JP2004511495A (fr)
KR (1) KR20030082542A (fr)
CN (1) CN1582178A (fr)
AP (1) AP2003002800A0 (fr)
AU (1) AU1632002A (fr)
BR (1) BR0114639A (fr)
CA (1) CA2462073A1 (fr)
IL (1) IL155413A0 (fr)
WO (1) WO2002031110A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
JP2007518699A (ja) * 2003-04-18 2007-07-12 ノーウッド・イミュノロジー・リミテッド 胸腺再生前の病気の予防およびワクチン接種
CN101952454B (zh) 2008-02-08 2014-06-04 米迪缪尼有限公司 具有减弱的Fc配体亲和性的抗IFNAR1抗体
PT2635607T (pt) 2010-11-05 2019-12-11 Zymeworks Inc Design de anticorpo heterodimérico estável com mutações no domínio do fc

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014853A1 (fr) * 1994-11-10 1996-05-23 University Of Washington Implantation intrathymique de cellules souches
WO2000062657A2 (fr) * 1999-04-15 2000-10-26 Monash University Amelioration de l'immunite induite par les lymphocytes t

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014853A1 (fr) * 1994-11-10 1996-05-23 University Of Washington Implantation intrathymique de cellules souches
WO2000062657A2 (fr) * 1999-04-15 2000-10-26 Monash University Amelioration de l'immunite induite par les lymphocytes t

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BONYHADI M. ET AL: "RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem-progenitor cells inhibit human immunodeficiency virus replication", J. VIROL., vol. 71, no. 6, 1997, pages 4707 - 4716, XP002969707 *
FABRIS N. ET AL: "Plasticity of neuro-endocrine-thymus interaction during aging", CELLULAR AND MOLEC. BIOL., vol. 43, no. 4, 1997, pages 529 - 541, XP002969786 *
GREENSTEIN B. ET AL: "Regeneration of the thymus in old male rats treated with a stable analogue of LHRH", J. ENDOCR., vol. 112, 1987, pages 345 - 350, XP002969788 *
NIKOLIC B. ET AL: "A novel application of cyclosporin A in nonmyeloablative pretransplant host conditioning for allogeneic BMT", BLOOD, vol. 96, no. 3, August 2000 (2000-08-01), pages 1166 - 1172, XP002969706 *
PENIT C. ET AL: "Cell proliferation and thymocyte subset reconstitution in sublethally irradiated mice: Compared kinetics of endogenous and intrathymically transferred progenitors", PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 5547 - 5551, XP002969787 *

Also Published As

Publication number Publication date
CN1582178A (zh) 2005-02-16
KR20030082542A (ko) 2003-10-22
AU1632002A (en) 2002-04-22
WO2002031110A2 (fr) 2002-04-18
IL155413A0 (en) 2003-11-23
EP1357978A2 (fr) 2003-11-05
JP2004511495A (ja) 2004-04-15
BR0114639A (pt) 2004-01-20
CA2462073A1 (fr) 2002-04-18
EP1357978A4 (fr) 2004-05-19
AP2003002800A0 (en) 2003-06-30

Similar Documents

Publication Publication Date Title
Han et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases
Fu et al. Human mesenchymal stem cell treatment of premature ovarian failure: new challenges and opportunities
Kim et al. Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice
AU2020201856A1 (en) Methods modulating immunoregulatory effect of stem cells
CN104873540B (zh) 多潜能成体祖细胞的免疫调节特性及其用途
Le Blanc et al. Mesenchymal stem cells: properties and role in clinical bone marrow transplantation
Sudres et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice
Khan et al. A comparison of phenotypic and functional properties of mesenchymal stromal cells and multipotent adult progenitor cells
ES2623141T3 (es) Nuevos métodos para modular respuestas inflamatorias y/o inmunitarias
CN105560284A (zh) 脑损伤和疾病的mapc治疗
JP2004521877A5 (fr)
CA2567177A1 (fr) Cellules genetiquement modifiees pour applications therapeutiques
Mishra Bone marrow-derived mesenchymal stem cells for treatment of heart failure: is it all paracrine actions and immunomodulation?
WO2006078782A3 (fr) Compositions contenant des cellules d'agm et procedes pour les utiliser
Lv et al. Umbilical cord mesenchymal stem cell therapy for regenerative treatment of rheumatoid arthritis: opportunities and challenges
Chen et al. The latest developments in immunomodulation of mesenchymal stem cells in the treatment of intrauterine adhesions, both allogeneic and autologous
Vandermeulen et al. Rationale for the potential use of mesenchymal stromal cells in liver transplantation
Saad-Naguib et al. Impaired receptivity of thin endometrium: therapeutic potential of mesenchymal stem cells
Li et al. Anti-inflammatory effect of dental pulp stem cells
WO2020210458A1 (fr) Thérapie par ultrasons focalisés pulsés pour le traitement de troubles du pancréas
WO2002030259A3 (fr) Prevention de maladies par reactivation du thymus
US20020142462A1 (en) Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood
WO2002031110A3 (fr) Therapie genique aux cellules souches hematopoietiques
JP2008503587A (ja) 幹細胞をホーミングさせるためのｃｃｒリガンド
Sadeghi et al. Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002534480

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 155413

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020037005255

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001986714

Country of ref document: EP

Ref document number: 2003/03685

Country of ref document: ZA

Ref document number: 2002216320

Country of ref document: AU

Ref document number: 525827

Country of ref document: NZ

Ref document number: 200303685

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: AP/P/2003/002800

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 018201385

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020037005255

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001986714

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2462073

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2002216320

Country of ref document: AU

Date of ref document: 20011012

Kind code of ref document: B

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载